Transtympanic Micropressure Applications as a Treatment of Meniere Disease

This policy addresses transtympanic micropressure therapy (Meniett device) for symptomatic treatment of vertigo in patients with Ménière disease—typically delivered via a tympanostomy/ventilation tube with brief patient‑administered pressure applications—and is considered for unilateral disease refractory to conservative medical management or persistent vertigo after tube placement. Major limitations: the policy deems the therapy not medically necessary/not covered due to insufficient, low‑quality and heterogeneous evidence (randomized trials do not demonstrate clear benefit vs placebo), FDA 510(k) clearance is limited to symptomatic use, and the policy is inactive for current claims adjudication.

"Conservative therapy for Meniere's disease including low-sodium diet and daily vasodilator and diuretic therapy to reduce fluid accumulation and vestibular symptoms."